Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25779374 | 0.86 | LMNA (0.33) | LMNA | |
| SCHEMBL25779389 | 0.85 | CYP3A4 (0.36) | CYP3A4HTTMEN1THRBKMT2A | |
| SCHEMBL26704925 | 0.80 | SPHK1 (0.40) | CYP3A4HTTMEN1THRBKMT2A | |
| SCHEMBL12787614 | 0.80 | CPB2 (0.39) | MEN1KMT2AOPRM1LMNA | |
| SCHEMBL26465757 | 0.79 | MEN1 (0.48) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL27861168 | 0.79 | DNM1 (0.42) | CYP3A4HTTMEN1THRBKMT2A | |
| SCHEMBL16072507 | 0.78 | — | — | |
| SCHEMBL26465758 | 0.76 | KDM4E (0.44) | LMNA | |
| SCHEMBL25779336 | 0.74 | MEN1 (0.42) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL17780065 | 0.74 | LMNA (0.39) | CYP3A4HTTMEN1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139745-A1 | NON-PEPTIDIC POLYMERIC LINKER COMPOUND, CONJUGATE COMPRISING SAME LINKER COMPOUND, AND METHODS FOR PREPARING SAME LINKER COMPOUND AND CONJUGATE | HANMI PHARM. CO., LTD. (KR) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139745-A1 | NON-PEPTIDIC POLYMERIC LINKER COMPOUND, CONJUGATE COMPRISING SAME LINKER COMPOUND, AND METHODS FOR PREPARING SAME LINKER COMPOUND AND CONJUGATE | FCGR1A, FCGR3B, FCGR2A | CYP3A4 2427/4885HTT 3694/4885MEN1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.